455 related articles for article (PubMed ID: 18848503)
61. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Gonzalez-Lama Y; Fernandez-Blanco I; Lopez-SanRoman A; Taxonera C; Casis B; Tabernero S; Bermejo F; Martinez-Silva F; Mendoza JL; Martinez-Montiel P; Carneros JA; Sanchez F; Maté J; Gisbert JP;
Hepatogastroenterology; 2008; 55(86-87):1609-14. PubMed ID: 19102352
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients.
Gavalas E; Kountouras J; Stergiopoulos C; Zavos C; Gisakis D; Nikolaidis N; Giouleme O; Chatzopoulos D; Kapetanakis N
Hepatogastroenterology; 2007 Jun; 54(76):1074-9. PubMed ID: 17629042
[TBL] [Abstract][Full Text] [Related]
63. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
64. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
Jess T; Loftus EV; Velayos FS; Winther KV; Tremaine WJ; Zinsmeister AR; Scott Harmsen W; Langholz E; Binder V; Munkholm P; Sandborn WJ
Am J Gastroenterol; 2007 Apr; 102(4):829-36. PubMed ID: 17222314
[TBL] [Abstract][Full Text] [Related]
65. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease.
Brooks AJ; Begg EJ; Zhang M; Frampton CM; Barclay ML
Ther Drug Monit; 2007 Oct; 29(5):619-25. PubMed ID: 17898653
[TBL] [Abstract][Full Text] [Related]
66. Risk of lymphoma in inflammatory bowel disease.
Loftus EV; Tremaine WJ; Habermann TM; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2000 Sep; 95(9):2308-12. PubMed ID: 11007233
[TBL] [Abstract][Full Text] [Related]
67. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.
Ljung T; Thomsen OØ; Vatn M; Karlén P; Karlsen LN; Tysk C; Nilsson SU; Kilander A; Gillberg R; Grip O; Lindgren S; Befrits R; Löfberg R
Scand J Gastroenterol; 2007 Feb; 42(2):221-7. PubMed ID: 17327942
[TBL] [Abstract][Full Text] [Related]
68. Anal carcinoma in inflammatory bowel disease.
Frisch M; Johansen C
Br J Cancer; 2000 Jul; 83(1):89-90. PubMed ID: 10883673
[TBL] [Abstract][Full Text] [Related]
69. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Mossop H; Davies P; Murphy MS
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
[TBL] [Abstract][Full Text] [Related]
70. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease.
García Rodríguez LA; Ruigómez A; Panés J
Gastroenterology; 2006 May; 130(6):1588-94. PubMed ID: 16697722
[TBL] [Abstract][Full Text] [Related]
71. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
72. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
73. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
[TBL] [Abstract][Full Text] [Related]
74. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Gisbert JP; Panés J
Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
[TBL] [Abstract][Full Text] [Related]
75. General principles of medical therapy of inflammatory bowel disease.
Friedman S
Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
[TBL] [Abstract][Full Text] [Related]
76. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine.
Seksik P; Cosnes J; Sokol H; Nion-Larmurier I; Gendre JP; Beaugerie L
Aliment Pharmacol Ther; 2009 May; 29(10):1106-13. PubMed ID: 19222411
[TBL] [Abstract][Full Text] [Related]
77. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.
Veereman-Wauters G; de Ridder L; Veres G; Kolacek S; Fell J; Malmborg P; Koletzko S; Dias JA; Misak Z; Rahier JF; Escher JC;
J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):830-7. PubMed ID: 22584748
[TBL] [Abstract][Full Text] [Related]
78. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
[TBL] [Abstract][Full Text] [Related]
79. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
80. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.
Maser EA; Deconda D; Lichtiger S; Ullman T; Present DH; Kornbluth A
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1112-6. PubMed ID: 18928936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
